Physiomics to Attend ASCPT 2025 Annual Meeting in Washington, DC
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce its attendance at the upcoming ASCPT 2025 Annual Meeting, taking place May 28-30, 2025, in Washington, DC.
The American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting is a leading global event bringing together researchers, industry leaders, and regulatory experts to advance the science and application of clinical pharmacology and translational medicine. The event showcases the latest developments in model-informed drug development (MIDD), pharmacometrics and quantitative clinical pharmacology, with this years’ event theme being “Patient-Centric Clinical Pharmacology: A Journey from Discovery to Recovery”.
Representing Physiomics at ASCPT will be Hayley Close, Head of Business Development, and Dr Mark Davies, Head of Quantitative Pharmacology and Data Science. Their objective is to engage with peers and prospective partners to explore how Physiomics’ integrated expertise in modelling & simulation, biostatistics, and data science can support more informed, efficient, and de-risked drug development.
“We’re looking forward to connecting with organisations preparing for first-in-human trials, or those engaging in clinical development looking to optimise dosing strategies through quantitative approaches,” said Hayley Close. “ASCPT provides a fantastic opportunity to engage with teams driving innovation in translational science and clinical pharmacology.”
If you would like to arrange a meeting during the event, please reach out at info@physiomics.co.uk. For more information about Physiomics’ services, please visit www.physiomics.co.uk.
Enquiries:
Physiomics plc
Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.